Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ernesto E. Mónaco"'
Autor:
Núria Milà Ràfols, Alejandro Rodríguez-Molinero, Antonio Chamero Pastilla, Gemma Añaños Carrasco, Carlos Pérez-López, Antonio García, César Gálvez-Barrón, Ezequiel A. Rodríguez Gullello, Ernesto E. Mónaco, Isabel Collado Pérez, Antonio Miñarro
Publikováno v:
Medicina Clinica (English Ed.)
Medicina Clinica
Medicina Clínica (English Edition)
Medicina Clínica
Medicina Clinica
Medicina Clínica (English Edition)
Medicina Clínica
To analyze whether there is an association between the use glucocorticoids at high doses, and the evolution of saturation/fraction of inspired oxygen (SAFI) or time to discharge, in patients hospitalized with COVID-19.This was an observational study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::085774f687ffcfbae85ed9d698b43712
https://doi.org/10.1016/j.medcli.2020.08.003
https://doi.org/10.1016/j.medcli.2020.08.003
Autor:
Maria Teresa Sáenz Robles, Gemma Tremosa Llurba, María Dolores Dapena, César Gálvez-Barrón, Antonio Chamero Pastilla, Anna Alberti Casas, Manel Borrego Ruiz, Ezequiel Rodríguez, Andreu Fenollosa Artés, Núria Milà Ràfols, Yris M. Sanchez Rodriguez, Mireia Martín Puig, Enric Sabria Bach, Ana M. Capielo Fornerino, Ernesto E. Mónaco, Oscar Macho, Gemma Añaños Carrasco, Natàlia Vidal Meler, Maria del Mar Segura Martin, Alejandro Rodríguez-Molinero, Florencia I. Venturini Cabanellas, José C. Molina Hinojosa, Sergi Martínez, Gabriela F López, Antonio Miñarro, Italo G. Pisani Zambrano, Isabel Collado Pérez, Jose L. Avalos Garcia, Clara Gris Ambros, Ester Ventosa Gili, Lourdes Hernandez Martinez, Carlos Pérez-López, Juan P. Rives, Laura Peramiquel Fonollosa, Pedro L. Campo Pisa, Antonio García
Publikováno v:
One Health
Dipòsit Digital de la UB
Universidad de Barcelona
One Health, Vol 12, Iss, Pp 100214-(2021)
Dipòsit Digital de la UB
Universidad de Barcelona
One Health, Vol 12, Iss, Pp 100214-(2021)
Background Tocilizumab has been proposed as a treatment for the new disease COVID-19, however, there is not enough scientific evidence to support this treatment. The objective of this study is to analyze whether the use of tocilizumab is associated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::535430b6969786d74bc124356fabfb74
http://hdl.handle.net/2445/175269
http://hdl.handle.net/2445/175269
Autor:
Alejandro Rodríguez-Molinero, Carlos Pérez-López, César Gálvez-Barrón, Antonio Miñarro, Oscar Macho, Gabriela F. López, Maria Teresa Robles, Maria Dolores Dapena, Sergi Martínez, Ezequiel Rodríguez, Isabel Collado Pérez, Anna Alberti Casas, Jose L. Avalos Garcia, Manel Borrego Ruiz, Gemma Añaños Carrasco, Pedro L. Campo Pisa, Ana M. Capielo Fornerino, Antonio Chamero Pastilla, Andreu Fenollosa Artés, Clara Gris Ambros, Lourdes Hernandez Martinez, Antonio Hidalgo García, Mireia Martín Puig, Núria Milà Ràfols, José C. Molina Hinojosa, Ernesto E. Monaco, Laura Peramiquel Fonollosa, Italo G. Pisani Zambrano, Juan P. Rives, Enric Sabria Bach, Yris M. Sanchez Rodriguez, Maria del Mar Segura Martin, Gemma Tremosa Llurba, Ester Ventosa Gili, Florencia I. Venturini Cabanellas, Natàlia Vidal Meler
Publikováno v:
One Health, Vol 12, Iss , Pp 100214- (2021)
Background: Tocilizumab has been proposed as a treatment for the new disease COVID-19, however, there is not enough scientific evidence to support this treatment. The objective of this study is to analyze whether the use of tocilizumab is associated
Externí odkaz:
https://doaj.org/article/b6eebaaabd874c61996ea74b63265e48